

ASX RELEASE

1 December 2022

Final Director's Interest Notice – Appendix 3Z: Dr John Lambert

Appendix 3Z – Final Director's Interest Notice for Dr. John Lambert is attached.

This ASX announcement was approved and authorised for release by the Company Secretary of Amplia Therapeutics Limited.

- End -

For further information:

Andrew J. Cooke
Company Secretary
andrew@ampliatx.com
www.ampliatx.com

About Amplia Therapeutics Limited

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus in pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF).

Appendix 3Z

Final Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	Amplia Therapeutics Limited
ABN	16 165 160 841

We (the entity) give ASX the following information under listing rule 3.19A.3 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of director	John Nicholas Lambert
Date of last notice	5 September 2022
Date that director ceased to be director	30 November 2022

Part 1 – Director's relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Number & class of securities
1,070,000 Options
(i) Exercise Price: \$0.155
(ii) 4 years vesting (accelerated upon completion of Phase 1 trial);
(iii) Fully vested in a change of control;
(iv) Expire 24 June 2024.
162,500 fully paid shares
10,834 ATXO Listed Options Ex Price \$0.28 Exp 31 Dec 2023

+ See chapter 19 for defined terms.

Appendix 3Z Final Director's Interest Notice

Part 2 – Director's relevant interests in securities of which the director is not the registered holder

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of interest Note: Provide details of the circumstances giving rise to the relevant interest	Number & class of securities
LLAC Investments Pty Ltd <Ralph Super Fund A/C> of which Dr. Lambert is a Director and beneficiary.	275,000 fully paid shares 18,334 ATXO Listed Options - Ex Price \$0.28 Exp Date 31 Dec 2023

Part 3 – Director's interests in contracts

Detail of contract	Nil
Nature of interest	
Name of registered holder (if issued securities)	
No. and class of securities to which interest relates	

1 December 2022

+ See chapter 19 for defined terms.